Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic Cancer
Cancer Science · 2025
DOI: 10.1111/cas.16456 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Dan Su und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Precision Medicine, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Plan of Heilongjiang Provincial Health Commission, Haiyan Foundation of Harbin Medical University Cancer Hospital.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with poor prognosis and limited treatment options. While the majority of PDAC cases harbor KRAS mutations, approximately 8%–10% are KRAS wild‐type (KRAS‐WT). These KRAS‐WT tumors often contain actionable mutations and gene fusions, making them more suitable for precision therapies. Identifying these molecular alterations is crucial for improving outcomes in this subset of patients. This retrospective study involved 34 patients with KRAS‐WT PDAC. Genomic profiling was performed using next‐generation sequencing (NGS) and RNA sequencing to detect mutations and fusions. Comparative analysis was conducted with TCGA‐PAAD data, and immune infiltration was assessed using bioinformatic deconvolution methods. Targetable alterations were identified in multiple pathways. Key mutations included ATM (18%), PIK3CA (15%), and ROS1 (15%), while actionable gene fusions such as CCDC6‐RET and ETV6‐NTRK3 were present in 10.3% of patients. The gene mutations associated with homologous recombination deficiency (HRD) are predicted to increase sensitivity to platinum‐based chemotherapy ( p = 0.047). Tumors with epigenetic regulatory genes mutations (e.g., ARID1A, KMT2C/D) exhibited enhanced immune cell infiltration, highlighting potential responsiveness to immune checkpoint inhibitors (ICIs). Kinase fusions (NTRK and RET) were linked to response to larotinib and RET‐specific inhibitors, respectively. KRAS‐WT PDAC contains actionable mutations and fusions, offering significant potential for targeted and immune‐based therapies. Further clinical studies are needed to validate these therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- Key Laboratory of Tumor Immunology in Heilongjiang, Harbin, China.
- Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin, China.
- Department of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
- Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
ORCID-Profile: Yanqiao Zhang
Förderung
- Science and Technology Plan of Heilongjiang Provincial Health Commission
- Haiyan Foundation of Harbin Medical University Cancer Hospital
Zitieren
APA
Su, D., Ruan, Y., Shi, Y., Cao, D., Wu, T., Dang, T., Wang, H., Xin, Y., Ma, M., Meng, H., Liu, C., & Zhang, Y. (2025). Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic Cancer. Cancer Science. https://doi.org/10.1111/cas.16456
Vancouver
Su D, Ruan Y, Shi Y, Cao D, Wu T, Dang T, et al. Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic Cancer. Cancer Science. 2025. doi:10.1111/cas.16456
BibTeX
@article{Su2025,
author = {Su, Dan and Ruan, Yuli and Shi, Yingfei and Cao, Dandan and Wu, Tong and Dang, Tianjiao and Wang, Hong and Xin, Yaqun and Ma, Ming and Meng, Hongxue and Liu, Chao and Zhang, Yanqiao},
title = {Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic Cancer},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16456}
}
EUVIMED